Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
暂无分享,去创建一个
R. Rosenheck | J. Cramer | D. Charney | W. Henderson | J. Erdos | L. Frisman | E. Allan | W. Henderson | J. Cramer | Jonathan Thomas | Weichun Xu | W. Xu | J. Thomas
[1] M. Gold. Cost-effectiveness in health and medicine , 2016 .
[2] D. Luchins,et al. Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends. , 1998, Psychiatric services.
[3] R. Rosenheck,et al. Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1998, Archives of general psychiatry.
[4] J. Lave,et al. Cost-effectiveness of treatments for major depression in primary care practice. , 1998, Archives of general psychiatry.
[5] R. Rosenheck,et al. Cost-effectiveness of intensive psychiatric community care for high users of inpatient services. , 1998, Archives of general psychiatry.
[6] W. Reid,et al. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. , 1998, The Journal of clinical psychiatry.
[7] S. Essock,et al. Cost-effectiveness of assertive community treatment teams. , 1998, The American journal of orthopsychiatry.
[8] T. Hu,et al. Cost-Outcome Methods for Mental Health , 1997 .
[9] R. Rosenheck,et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.
[10] M. Johannesson,et al. Theory and methods of economic evaluation of health care. , 1996, Developments in health economics and public policy.
[11] R. Conley,et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. , 1995, The American journal of psychiatry.
[12] S Pollack,et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. , 1994, The American journal of psychiatry.
[13] Ruth E. Brown,et al. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. , 1990, Hospital & community psychiatry.
[14] G Honigfeld,et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.
[15] B. Weisbrod,et al. Alternative to mental hospital treatment. II. Economic benefit-cost analysis. , 1980, Archives of general psychiatry.
[16] G. Simpson,et al. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS , 1970, Acta psychiatrica Scandinavica. Supplementum.
[17] J. Overall,et al. The Brief Psychiatric Rating Scale , 1962 .
[18] Nancy H. Covell,et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. , 1996, Psychopharmacology bulletin.
[19] R. Rosenheck,et al. Multisite experimental cost study of intensive psychiatric community care. , 1995, Schizophrenia bulletin.
[20] R. Buchanan. Clozapine: efficacy and safety. , 1995, Schizophrenia bulletin.
[21] Milton C. Weinstein,et al. Valuing health care: From cost–effectiveness ratios to resource allocation: where to draw the line? , 1995 .
[22] R. Rosenheck,et al. Who should receive high-cost mental health treatment and for how long? , 1993, Schizophrenia bulletin.
[23] B. Snitz,et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. , 1993, The American journal of psychiatry.
[24] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.
[25] W T Carpenter,et al. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. , 1984, Schizophrenia bulletin.